AI Takeaway
VTR (Ventas) delivered strong Q1 FY2026 results with revenue surging 22.0% year-over-year to $1.66B, driven by robust operating cash flow growth of 22.9%, while stockholders' equity expanded 14.4% reflecting a healthier balance sheet.
Revenue
$1.66B
++22.01% YoY
EPS (Basic)
$0.12
++9.09% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-Q filing
VTR reported Q1 FY2026 revenue of $1.66B, up 22.0% from $1.36B in the prior-year period, indicating meaningful portfolio expansion and/or improved occupancy and rental rate trends across its healthcare real estate assets.
Source: Source: 10-Q Financial Data (Income Statement)
Operating cash flow grew 22.9% year-over-year to $394.6M from $321.1M, demonstrating improved cash generation capability that supports dividend sustainability and reinvestment capacity.
Source: Source: 10-Q Financial Data (Cash Flow Statement)
Investing cash outflows increased to -$1.07B from -$883.7M (a 20.9% increase in outflows), suggesting VTR continued to deploy capital aggressively into acquisitions or development projects to grow its portfolio.
Source: Source: 10-Q Financial Data (Cash Flow Statement)
2 more insights available
Upgrade to unlockVTR deployed over $1.07B in investing activities in Q1 FY2026 alone, maintaining a debt-to-equity ratio of ~1.08. Sustained high capital expenditure financed by debt could pressure the balance sheet if interest rates remain elevated or asset values decline.
Source: Source: 10-Q Financial Data (Balance Sheet & Cash Flow Statement)
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $0.11 versus the $0.12 analyst consensus — a -11.4% miss for Q1 FY2026.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $1.66B | $1.36B | +22.01% |
EPS (Basic) | $0.12 | $0.11 | +9.09% |
EPS (Diluted) | $0.11 | $0.10 | +10.00% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $27.69B | $26.03B | +6.35% |
Total Liabilities | $14.11B | $14.17B | -0.40% |
Stockholders' Equity | $13.12B | $11.47B | +14.43% |
Cash & Equivalents | $183.61M | $182.34M | +0.70% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $394.61M | $321.14M | +22.88% |
Investing Cash Flow | $-1.07B | $-883.74M | -20.91% |
Financing Cash Flow | $89.96M | $-149.14M | +160.32% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Debt to Equity | $1.075 | — | — |
Other companies in Health Care REITs
VTR's revenue grew 22.0% year-over-year in Q1 FY2026, rising to $1.66B from $1.36B in the prior-year period. This strong growth likely reflects portfolio expansion through acquisitions and improved performance across its healthcare real estate assets.
The key takeaways from VTR's Q1 FY2026 results include 22.0% revenue growth to $1.66B, operating cash flow expansion of 22.9% to $394.6M, and over $1.07B deployed in investment activities. The balance sheet also strengthened with stockholders' equity rising 14.4% to $13.12B.
VTR's financial health appears solid with a debt-to-equity ratio of approximately 1.08 and growing operating cash flow of $394.6M. However, cash reserves are relatively thin at $183.6M, and the company is actively investing, suggesting reliance on capital market access for liquidity.
Based on the financial data, key risks for VTR include interest rate sensitivity given $14.11B in total liabilities, heavy capital deployment of over $1.07B in a single quarter, and EPS growth of only 9.1% lagging far behind 22.0% revenue growth, suggesting dilution from equity issuances.
Yes, VTR's basic EPS improved to $0.12 in Q1 FY2026, up 9.1% from $0.11 in the prior-year period, and diluted EPS rose 10.0% to $0.11. However, EPS growth significantly lagged revenue growth of 22.0%, likely due to an increased share count from equity issuances used to fund acquisitions.